Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients

• Egile Nagusiak: Sasan Roayaie (Egilea), Patricia A. Sheiner (Egilea), Sukru Emre (Egilea), Steven Guy (Egilea), Myron E. Schwartz (Egilea), Peter Boros (Egilea), Charles M. Miller (Egilea)
• Formatua: Liburua
• Argitaratua: Hindawi Limited, 2000-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

OKT3, a murine monoclonal antibody specific to the human CD3 complex, induces immunosuppression by depletion of T cells. Administration of OKT3 results in significant release of proinflammatory cytokines, such as TNFα and IL1β. Liver recipients who experience rejection within 3 weeks after transplan...